EUCTR2011-005230-18-GB进行中（未招募）不适用
A Phase III randomized trial of metformin versus placebo on recurrence and survival in early stage breast cancer. - MA.32
CIC Clinical Trials Group0 个研究点目标入组 3,582 人开始时间: 2012年5月9日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 3,582
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subjects must have histologically confirmed invasive breast cancer and be enrolled in the trial within 12 months after the first histologic diagnosis of invasive breast cancer. 2. All subjects (both adjuvant and neo-adjuvant) must have sentinel lymph node biopsy and/or axillary lymph node dissection. 3.Definitive surgery and/or chemotherapy must have been completed at least 4 weeks prior to randomization. 4. Adjuvant subjects with the following pT pN combinations are eligible: • pT1c, pN0 AND at least one of the following tumour characteristics: histologic grade 3, lymphovascular invasion, negative estrogen and progesterone receptors, HER2 positive, Oncotype Dx recurrence score > 25 (or if Oncotype Dx recurrence score is not available, Ki67 > 14%)OR • Subjects with pT2-3, pN0 OR • Subjects with pT1-3, pN1-3. The eligibility of neo-adjuvant subjects is assessed on the basis of cTNM. The same eligible TNM combinations apply. 5. Estrogen and progesterone receptor status must be known. 6. HER2 status must be known. 7. Patients must have had a bilateral mammogram within 12 months prior to randomization, unless the initial surgery was a total mastectomy, in which case only a mammogram of the remaining breast is required. 8. The following scans must have been performed between the first diagnosis and the time of randomization: • Chest X-Ray (or Chest CT) is mandatory • Bone scans (with x-rays of abnormal areas) if symptoms of metastatic disease • Abdominal imaging is required if liver function tests are abnormal or if there are symptoms of metastatic disease 9. Adequate haematology (exact definition in protocol) 10. Adequate biochemistry (exact definition in protocol) 11. ECOG Performance Status of 0,1 or 2 12. Age > 18 and < 75 13. Subjects must be accessible for treatment and follow-up. 14. Patients must have provided written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 170
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •1. Subjects with a history of other malignancies (exact definition in protocol). 2. Subjects with locally recurrent or metastatic breast carcinoma. 3. Subjects whose axillary node status is unknown. 4. Known diabetes (type 1 or 2) or baseline fasting glucose > 7.0 mmol/L (126 mg/dL). 5. Known hypersensitivity or intolerance of metformin. 6. Any condition associated with increased risk of metformin-associated lactic acidosis (exact definition in protocol). 7. Currently taking metformin, sulfonylureas, thiazolidenediones or insulin for any reason. 8. Current or planned pregnancy or lactation in women of child-bearing potential (confirmed by negative pregnancy test within 7 days of randomization). Men should not father a child. Birth control requirements are defined in the protocol. 9. Concurrent or planned participation in randomized trials of weight loss, exercise or trials targeting insulin and its pathways.
研究者
相似试验
进行中（未招募）
不适用
A Prospective Randomised Pilot Study of Metformin and Lifestyle Intervention in the Prevention of Metabolic Syndrome due to Androgen Deprivation Therapy in Prostate Cancer - Metformin use in patients on ADT to prevent Metabolic SyndromePatients with prostate cancer on androgen deprivation therapy (ADT). Randomisation between standard treatment with ADT only, and the additional use of metformin with dietary and exercise advice.Aim is to reduce the prevalence of metabolic syndrome in the intervention arm - this is a condition linked to ADT in prostate cancer patientsMedDRA version: 9.1Level: LLTClassification code 10001186Term: Adenocarcinoma of prostateMedDRA version: 9.1Level: LLTClassification code 10052066Term: Metabolic syndromeEUCTR2007-002815-20-GBRoyal Surrey County Hospital
进行中（未招募）
1 期
A randomised study of the effect of metformin and exercise in overweight women with polycystic ovary syndrome - Metformin-exercise projectPolycystic ovary syndrome is a condition characterized by obesity, anovulation and hyperandrogenism/hyperandrogenemia. Insulin resistance is common, and treatment is aimed at reducing this.EUCTR2004-004257-26-DKOrganisation name was not entered
进行中（未招募）
1 期
Clinical pilot study on the effect of Metformin in adipose children and adolescents with insulin-resistanceKlinische Pilotstudie zur Untersuchung der Wirkung von Metformin bei adipösen Kindern und Jugendlichen mit Insulin-Resistenz (IR) - not availableInsuline-resistance in adipose children and adolescentsEUCTR2004-003816-47-DEPädiatrische Endokrinologie, Universitätsmedizin Berlin, Charité
招募中
3 期
empagliflozin effect in polycystic ovarian syndromPolycystic ovarian syndrome.Polycystic ovarian syndromeE28.2IRCT20220822055771N1Shahre-kord University of Medical Sciences50
招募中
4 期
Young women and weight loss study 2007Obesity in young womenDiet and Nutrition - ObesityACTRN12607000213448Commonwealth Scientific Industrial Research Organisation, Human Nutrition300